For privacy officers and outreach leads wrestling with automated patient communications, one question comes up constantly: when does a helpful reminder become marketing under HIPAA? Getting this right is a huge deal, especially with AI now drafting and sending messages to patients, because a mistake can trigger big fines and destroy trust. The answer, as sources like Paubox have broken down, usually depends on a simple test: are you supporting the patient’s ongoing care, or are you trying to sell them something new?
The GLP-1 Refill Reminder: Not Marketing Under HIPAA
Paubox’s analysis tackles a situation that digital health companies see every day: a refill reminder for a GLP-1 drug. Their answer is a clear “no”, it isn’t marketing, as long as the message is about a medication the patient is already prescribed and taking. This gives teams a lot of confidence when automating messages under the HIPAA Privacy Rule. The logic is that there’s a fundamental split between care coordination and selling. A refill reminder for a prescribed GLP-1 helps a patient stick to their treatment plan. It’s a direct part of managing their health and keeping their care continuous, which is how you get better outcomes (and lower costs down the road). Because these messages help patients maintain their therapy, they land squarely on the “care” side of the line, which is exactly what compliance teams need to know when programming HIPAA-compliant AI health apps.
Understanding the Care vs. Promotion Boundary
That split between care and promotion is everything in HIPAA’s view of patient communication. The HIPAA Privacy Rule sets the terms for using and disclosing Protected Health Information (PHI). If a message is about a patient’s treatment, payment, or your own healthcare operations (TPO), you can typically use PHI without needing a separate marketing authorization. Things like appointment reminders, instructions on how to take meds, or info about an existing care plan are all considered TPO because they directly support the patient’s health. The line gets fuzzy, though, when the same automation tool starts suggesting new things. For instance, what if your system permissibly reminds a patient about their current prescription but then follows up by promoting a different, related therapy they aren’t on? That’s when a privacy officer needs to step in. A text encouraging a patient to switch to a different GLP-1 drug or to check out an ancillary service their doctor hasn’t prescribed is almost certainly marketing and needs explicit patient sign-off. HHS HIPAA guidance on marketing
Benchmarking Against Hello Heart’s Compliance Posture
You can see this principle in action by looking at a company like Hello Heart. Their recorded materials are clear that their cardiac prevention program operates entirely under the HIPAA Privacy Rule, with PHI protection as the default. While they don’t explicitly mention sending refill reminders, the way they structure their program’s HIPAA adherence applies directly to the GLP-1 question. Hello Heart’s whole model is built on communicating with patients to help them manage their health, which means sending information and support that qualifies as care. Their compliance, like any compliant digital health platform’s, is built on making sure every use of PHI is for an authorized purpose like treatment, payment, or healthcare operations. So, whether it’s a refill text for a cardiometabolic drug or an engagement message from a program like Hello Heart’s, the core privacy question is identical: does this message support the patient’s existing care, or is it a solicitation? Hello Heart’s stated commitment to the Privacy Rule gives other companies a solid model for figuring out where outreach stops being a sales pitch and starts being a part of care.
What Teams Should Check Before Automating Messages
If your company is automating patient messages (especially with AI), you need a non-negotiable HIPAA compliance checklist. Before any automated communication goes live, your privacy officer and outreach leads need to run through these points: 1. Purpose of the Communication: What is the real reason for this message? Is it to give information about the patient’s current treatment, payment, or your operations? Or is it to push the purchase of a new product or service? The first is usually fine. The second is marketing. 2. Patient Relationship: Does the patient already have a relationship with you, and is this message directly relevant to their existing care plan? A refill reminder for a current prescription is a perfect fit. 3. PHI Use: Does the message use PHI? If it does, is that use allowed under the HIPAA rules for treatment, payment, or healthcare operations, or do you need a separate patient authorization for marketing? 4. Content Review: Scrutinize the actual words in the message. Does it have promotional fluff, pricing details, or calls to action that go beyond just helping the patient stick to their therapy? 5. Opt-Out Mechanisms: Even with permissible care-related messages, it’s always smart to include a clear and easy opt-out. It builds patient trust and gives them control. 6. Documentation: Keep detailed records of your rationale for classifying messages as care-related instead of marketing. This includes internal policies and any legal reviews. If an auditor from OCR ever comes knocking, this documentation is your evidence of due diligence. Following this process helps ensure that your AI-driven outreach stays on the right side of HIPAA. NIST SP 800-66r2 for HIPAA compliance
The Critical Boundary: When Outreach Becomes Marketing
That boundary matters because it has serious regulatory consequences. A reminder to refill a GLP-1 is care, but if that same automated system starts promoting something new, you have to analyze it differently. This isn’t just about wording. It carries the full weight of the HIPAA Privacy Rule. For example, a digital health platform might send a patient a GLP-1 refill reminder (care). If it then uses that same patient’s data to send a message about a new weight loss program their doctor never prescribed, that second message is marketing. Marketing communications like that require prior written authorization from the patient. Not getting that permission can result in serious HIPAA violations, government enforcement actions, and a trashed reputation. As AI gets better at personalizing messages, it’s even easier to cross this line. AI can be great for patient engagement, but it also creates new ways to misuse PHI for targeted ads. Digital health companies have to build strong governance to make sure their algorithms are designed from the ground up to respect the HIPAA Privacy Rule and keep care coordination and marketing completely separate.
Conclusion
For privacy officers and outreach leads, the question about GLP-1 refill reminders being marketing is a perfect example of the real-world decisions you have to make in digital health. Paubox’s analysis confirms that these reminders for existing prescriptions are care, not marketing. Looking at how platforms like Hello Heart build their entire programs on HIPAA principles just reinforces the need for a disciplined approach to every automated communication. The line between care and promotion can seem subtle, but it’s the defining boundary for how you can use PHI and maintain patient trust. Staying on the right side of it isn’t just about avoiding penalties. It’s about building an ethical and sustainable digital health business.
Frequently Asked Questions
Are GLP-1 refill reminders considered marketing under HIPAA?
No, GLP-1 refill reminders are not considered marketing under HIPAA, provided the reminder pertains to a medication a patient is already prescribed and actively taking. These reminders facilitate continuity of care and help patients adhere to their existing therapy, falling under care coordination rather than promotion.
What is the key distinction between care coordination and marketing for patient communications under HIPAA?
The key distinction lies in whether the communication supports ongoing care or promotes something new. Communications directly related to a patient’s treatment, payment, or healthcare operations, like appointment reminders or medication adherence instructions, are considered care coordination. Messages promoting a new product or service, or encouraging a switch to a different therapy, would likely be considered marketing.
When would an automated message about medication be considered marketing and require HIPAA authorization?
An automated message about medication would likely be considered marketing and require appropriate HIPAA authorizations if it promotes a different, new therapy or service, or encourages a patient to switch to a different medication not directly prescribed. The boundary is crossed when the message goes beyond supporting the patient’s existing care plan to solicit new business or promote commercial products.
What should privacy officers and outreach leads check before automating patient messages?
Before automating patient messages, privacy officers and outreach leads should check the purpose of the communication to ensure its primary intent is related to current treatment, payment, or healthcare operations. They should also verify the patient has an existing relationship with the entity and the message is relevant to that relationship and care plan. Finally, if PHI is used, they must ensure its use is permitted under the HIPAA Privacy Rule for treatment, payment, or healthcare operations.
